Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Vinay Agrawal

Journal: Indian journal of ophthalmology 2014;61(8):433-4

PMID: 23925332

Free Full Text on PubMed Central View on PubMed

Abstract

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

Address: Consultant Cornea Services, Clear Vision, 201, Bhavya Plaza, Station Road, Khar (W), Mumbai, India.

DOI: 10.4103/0301-4738.116072

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

https://scite.ai/reports/23925332

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Collagen, Corneal Stroma, Corneal Topography, Cross-Linking Reagents, Humans, Keratoconus, Photochemotherapy, Photosensitizing Agents, Riboflavin, Treatment Outcome, Ultraviolet Rays, Visual Acuity